Brand Name | Status | Last Update |
---|---|---|
adreview | New Drug Application | 2024-01-10 |
Expiration | Code | ||
---|---|---|---|
IOBENGUANE I-131, AZEDRA, PROGENICS PHARMS INC | |||
2025-07-30 | ODE-204 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroblastoma | D009447 | EFO_0000621 | — | 11 | 14 | 2 | — | 10 | 36 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 4 | 4 | 1 | — | 2 | 9 |
Ganglioneuroblastoma | D018305 | — | — | 1 | — | 1 | — | — | 2 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pheochromocytoma | D010673 | — | — | 4 | 6 | — | — | 9 | 17 |
Paraganglioma | D010235 | — | — | 4 | 4 | — | — | 6 | 12 |
Neoplasms | D009369 | — | C80 | 1 | 4 | — | — | 2 | 7 |
Recurrence | D012008 | — | — | 1 | 2 | — | — | 3 | 6 |
Neuroectodermal tumors | D017599 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Retinoblastoma | D012175 | — | — | 1 | — | — | — | — | 1 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | — | 1 |
Thyroid diseases | D013959 | — | E00-E07 | 1 | — | — | — | — | 1 |
Carcinoid tumor | D002276 | — | D3A.00 | 1 | — | — | — | — | 1 |
Drug common name | Iobenguane i 131 |
INN | iobenguane (131i) |
Description | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. |
Classification | Small molecule |
Drug class | iodine-containing contrast media |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCc1cccc([131I])c1 |
PDB | — |
CAS-ID | 77679-27-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1615779 |
ChEBI ID | — |
PubChem CID | 60860 |
DrugBank | DB06704 |
UNII ID | Q461L7AK4R (ChemIDplus, GSRS) |